''We believe that Pluristem's cell source, combined with our proprietary cell manufacturing technology and strong intellectual property, will enable Pluristem to implement its business model and to enter into additional out-license agreements with pharmaceutical companies in the future for the marketing of disease-specific therapies.''

The last patient of our CLI Phase I study in the U.S. will complete a 12-month safety follow up by the end of October 2011. ''

''Furthermore, the granting of orphan drug status for Buerger's Disease will potentially enable us to accelerate the time to market, as it provides us with significant regulatory and financial benefits''

''The new facility is expected to commence operations at the end of 2012 and is expected to have the capacity to produce PLX cells for the treatment of over 150,000 patients annually.''

''Our new facility will support the manufacture of Pluristem’s PLX cell product candidates for the treatment of numerous inflammatory and ischemic disorders, including cardiovascular, musculoskeletal, pulmonary and autoimmune diseases''